Acute Coronary Syndrome

Cardiovascular diagnoses such as chest pain and atherosclerotic heart disease are key drivers of outpatient payments, which accounted for almost 57 percent of hospitals’ net patient revenue in 2017, according to data compiled by Definitive Healthcare.

Just half of Americans know the five common heart attack symptoms—even when presented with the symptoms as “yes” or “no” answers—based on 2017 results from the National Health Interview Survey (NHIS).

A new study of young heart attack sufferers revealed a sobering, albeit unsurprising, finding: More than 90 percent had at least one modifiable risk factor. What’s equally concerning, according to the authors, is the prevalence of most of these risk factors increased over the decade-long study.

ProvideGx, a subsidiary of Premier, will begin its offerings with metoprolol, a beta-blocker that can treat blood pressure and angina and is commonly given to heart attack patients.

Biologic treatment favorably modifies coronary plaque characteristics for patients with severe psoriasis, suggests a study published Feb. 5 in Cardiovascular Research. The findings raise the possibility that the anti-inflammatory drugs can both treat psoriasis and reduce cardiovascular risk.

The incidence of acute myocardial infarction (AMI) in pregnant women increased between 2005 and 2014, according to research published in the American Journal of Cardiology Jan. 25, but that hike was accompanied by decreases in mortality, cost of care and length of stay among expectant mothers.

An extended analysis of the ODYSSEY OUTCOMES trial has confirmed alirocumab, a PCSK9 inhibitor that hit the medical market in 2015, reduces a patient’s total risk of nonfatal and fatal cardiovascular events after an acute coronary syndrome (ACS).

Archeologists have uncovered evidence of atherosclerosis in a handful of 500-year-old mummies from Greenland, Forbes reported.

Aspirin offers modest protection against cardiovascular events in primary prevention, but that benefit is at least partially offset by an increase in major bleeding events, according to a meta-analysis published Jan. 22 in JAMA.

Higher concentrations of troponin—even those that were within a “normal range”—signal increased odds of adverse outcomes among outpatients with stable chest pain, suggesting the biomarker test may improve risk stratification and inform management strategies for this common clinical scenario.

Research published in the Journal of the American Heart Association Jan. 13 has concluded administering PCSK9 inhibitors to acute MI patients ahead of ischemia can mitigate the potential negative neurological effects that come with treatment.

Measuring blood levels of vaspin could independently predict major adverse cardiac events (MACE) in patients who have suffered acute myocardial infarction (AMI), according to research published Jan. 16 in the Journal of the American Heart Association, potentially improving early risk stratification in heart attack survivors.